Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

A team of US scientists has developed a new HIV vaccine that trains the immune system to overcome the virus's defenses, producing the strongest HIV-fighting antibody response ever reported in non-human primates.

The vaccine, developed by researchers from La Jolla Institute for Immunology (LJI), Scripps Research, and IAVI, is the first to generate a high number of broadly neutralizing antibodies against HIV in primates. Human trials have now begun.

“This feels like a huge success,” said LJI Professor and Chief Scientific Officer Shane Crotty.

“We constructed a successful vaccine from the ground up, which required a deep understanding of the immune system.” The findings are published in the journal Nature.

How Does The New Vaccine Work?

The vaccine is designed to guide the body's B cells—the immune cells responsible for making antibodies. Normally, B cells begin in a naïve state and gradually mature after encountering a virus. As they mature, they continuously refine the antibodies they produce, improving their ability to recognize and neutralize the virus.

Instead of waiting for this process to happen naturally, the new vaccine directs B cells through each stage of development.

Also read: US Hospital Performs World's First HIV-to-HIV Lung Transplant, Offering Fresh Hope for HIV Patients

The approach includes:

• A priming vaccine that activates naïve B cells.
• A series of booster shots that guide these cells toward producing broadly neutralizing antibodies capable of recognizing many HIV strains.

“This series of vaccinations will guide, or ‘walk’, a B cell from its naive state to its broadly neutralizing state,” said LJI Instructor Patrick Madden.

The scientists called this strategy germline targeting because it targets B cells before they begin their normal maturation process.

Strong Results in Animal Studies

To evaluate the vaccine, researchers tested it in rhesus macaques. The results showed:

• Around 44% of vaccinated animals produced broadly neutralizing antibodies against HIV.
• The antibody levels were unusually high compared with previous vaccine studies.
• The antibodies closely resembled those found in the small number of people who naturally develop broad protection against HIV.

“We succeeded in taking ultra-rare antibody responses and turning them into common responses by the end of the vaccination process,” Crotty said.

The researchers did not test whether the antibodies could completely prevent HIV infection. However, finding these antibodies circulating in the bloodstream suggests they could potentially recognize and block the virus.

Human Trials Underway

Read More: HIV No Longer Barrier To Organ Transplants, Say Delhi Doctors After Successful Kidney Surgery

The researchers are now working to improve the vaccine further, including refining the booster schedule to increase the number of individuals who develop broadly neutralizing antibodies.

“It was incredible to get those results, but of course we'd like to see a response in 100 percent of the animals,” Madden said.

According to the researchers, the antibodies produced in the vaccinated animals closely matched the broadly neutralizing antibodies seen in the rare people who naturally develop them.

“We believe this vaccine approach is even more likely to succeed in humans, because of the immunogenetics,” Crotty said.

Global Burden Of HIV

According to the World Health Organization, globally, 40.8 million [37.0–45.6 million] people were living with HIV at the end of 2024. Out of these, 1.3 million individuals newly acquired the virus, and 630,000 people died from AIDS-related illnesses.

To date, there is no vaccine available that will prevent HIV infection. Developing an HIV vaccine has remained one of the biggest challenges in medicine because the virus is exceptionally good at evading the immune system.

“The worldwide diversity of HIV mutations is extraordinary. Even the diversity within one individual person living with HIV is dramatic,” Madden said.

Endometriosis, a painful condition that affects around 1 in 10 women of reproductive age in the UK, takes an average of more than nine years to diagnose. That could soon change.

Based on the National Institute for Health and Care Excellence's (NICE) draft guidance, the NHS will roll out two non-invasive tests — the saliva-based Endotest and the gut sensor-based EndoSure — to help speed up the diagnosis of endometriosis in England and Wales.

NICE's draft early use healthtech guidance recommends the use of EndoSure and Endotest in the NHS during a three-year evidence generation period while additional data is collected on how well they work.

“The tests can be used to diagnose endometriosis in primary care, where current diagnostic accuracy can be limited by the availability of other tests and variation in expertise,” NICE said.

“A diagnosis of endometriosis can for some women take the best part of a decade, with the UK average standing at 9 years and 4 months, and rising to 11 years for those from ethnically diverse communities. That delay means living with chronic pelvic pain that affects daily life, relationships and work," said Dr. Anastasia Chalkidou, HealthTech Programme Director at NICE.

“The new technologies offer a less invasive, faster approach to receiving a diagnosis that does not rely on ultrasound operator expertise, potentially enabling earlier decision-making and reducing the need for unnecessary invasive investigations,” Chalkidou added.

Also read: Emma Barnett: It Took 21 Years To Diagnose My Endometriosis

What Is Endometriosis?

According to the World Health Organization (WHO), endometriosis is a disease in which tissue similar to the lining of the uterus grows outside the uterus. It can cause severe pelvic pain and make it difficult to conceive.

The condition can begin with a person's first menstrual period and last until menopause. It most commonly affects the ovaries, fallopian tubes and intestines, with pelvic pain and menstrual irregularities among the most common symptoms.

Diagnosis currently relies on ultrasound scans, MRI or laparoscopy, in which a camera is inserted through a small incision in the abdomen. Yet despite these diagnostic tools, women in England and Wales often wait as long as a decade for a diagnosis.

Those eventually diagnosed with endometriosis have reported that delays contribute to increased suffering, prolonged ill health and disease progression that can become more difficult to treat.

How Do EndoSure And Endotest Work?

READ: This Is Endometriosis, A Short Film On Debilitating Health Condition Wins BAFTA Award 2026, Know More

Endotest analyses a saliva sample to identify tiny biological markers called microRNAs that can indicate whether endometriosis is likely to be present. The sample is sent to a laboratory for analysis, and the results are returned to the treating healthcare professional to help guide diagnosis and care.

EndoSure is a non-invasive test that detects endometriosis by measuring electrical signals in the gut using sensor pads placed on the abdomen. Patients fast for six to eight hours before the test and drink water until full during the 45-minute procedure to help the device accurately record gut activity. Results are available immediately after the test.

“These technologies have the potential to change that by giving primary care professionals better non-invasive tools to identify endometriosis earlier, allowing earlier and better treatment,” Chalkidou said.

“Our draft guidance reflects our commitment to getting promising innovations to patients quickly, while making sure the evidence to support their wider use is built in a rigorous way.”

Who Can Use the Tests?

Both tests are intended to be used alongside standard clinical practice to support diagnosis, referral and management. They are not standalone diagnostic tests.

They should only be used in women in whom endometriosis is still suspected despite a normal clinical examination and either negative or inconclusive imaging results, or where imaging is unsuitable or unacceptable. The tests must be used by a healthcare professional.

Early economic modelling suggests both technologies could be cost-effective. During the evidence generation period, they will be funded through core NHS funding. The companies are responsible for organizing the evidence generation activities, and NICE will review progress annually.

A third test, DotEndo, needed more research before it could get the green light, Nice said.

Experts Welcome The Move

Endometriosis UK welcomed NICE's announcement, calling it "a major step forward in reducing disease impact and supporting those with endometriosis to live well with the disease."

The charity also said the rollout should be accompanied by better education for GPs and Practice Nurses to ensure prompt access to testing, earlier recognition of symptoms, and improved understanding of endometriosis, adenomyosis and other menstrual health conditions.

Dr Gail Busby, consultant gynecologist at Manchester University NHS Foundation Trust, called the tests "game-changer because they give us answers much earlier, without the need for invasive surgery, and that means we can start the right treatment sooner".

The FSSAI recently issued notices to three food business operators over what it described as misleading claims and labelling violations. The companies that have received notices are Heritage Foods Ltd for its paneer, Dia Foods for La Casa Vegan Hazelnut Chocolate Spread, and Cipzer Nutraceuticals for its juice capsules.

FSSAI Flags Down 3 Brands Over Misleading Claims

The food regulatory body directed the companies to provide explanations within seven days why action should not be initiated under the Food Safety and Standards Act, 2006.

The move is part of the regulator's broader ongoing crackdown on deceptive food packaging and marketing claims aimed at protecting consumers.

Also read: FSSAI Targets 6 Energy Drink Brands; Experts Link Them to Obesity, Liver Problems

Heritage Foods' Fresh Paneer Under FSSAI Scrutiny

FSSAI issued a notice to Heritage Foods, objecting to the use of the term “Fresh Paneer” on the packaging. It stated that the claim term does not meet the conditions laid down under Schedule V governing the use of the word “fresh”.

According to the regulator, the label “Fresh Paneer” is liable to mislead consumers because it does not satisfy the prescribed criteria for using the term.

La Casa Vegan Chocolate Spread Accused Of Misleading Claims

FSSAI also issued a notice to Dia Foods over its La Casa Vegan Hazelnut Chocolate Spread, alleging that several claims displayed on the packaging could mislead consumers. Among the claims questioned are:

• "All Natural"

• "100% Organic"

• "Vegan"

The regulator further pointed out that the product uses the phrase "100% Organic & Vegan”, which could be misleading as it has not obtained approvals like organic and vegan food.

Further, according to FSSAI, the packaging does not display the mandatory organic certification marks, including the Jaivik Bharat logo required under Indian regulations.

It also objected to its use of “100%” as the food regulatory body has stated that it cannot be defined under FSS Act, 2006.

Also read: Popular Biscuit Brand Under FSSAI Scrutiny For Misleading ‘100% Atta’ & ‘No Added Sugar’ Claims

Cipzer Nutraceutical Also Got Served

A third notice was issued to Cipzer Nutraceuticals over its juice capsules. FSSAI said the product carries claims that violate food labelling and advertising regulations.

In its notice, it said that the product carried the claim “FSSAI-approved” which could imply that FSSAI specifically endorsed it.

Other reasons listed in the complaint stated that the product boasted of claims like “Boost your immune system” and “remove toxins from your body”, which had no scientific backing. It also said the product’s packaging depicted pictures of various vegetables that were listed in the ingredient list.

The regulatory body added that the product also claimed the presence of Vitamin C and Vitamin E but failed to substantiate it scientifically.

The makers also claimed that the capsules are “made from organic vegetables”. FSSAI said that it could mislead the consumers as it does not carry the prescribed organic certification, including Jaivik Bharat Logo.

FSSAI’s Recent Crackdowns

The latest notices are part of FSSAI's ongoing crackdowns against misleading food claims. In recent weeks, the regulator has issued notices to several food companies over the use of terms like “100%,” “healthy,” “organic,” “natural,” and “fresh” as they do not comply with food labelling and advertising regulations.

The regulator has maintained that such claims can influence consumer purchasing decisions and must be scientifically substantiated and legally compliant.

Prominent brands that faced FSSAI scrutiny includes Red Bull Energy Drink, PepsiCo – Adrenaline Rush Energy Drink, Reliance Consumer Products – Campa Energy Gold Boost, Sting Energy Drink, Hell Energy, Coca-Cola-backed Monster, Eat Fit Digestive Biscuits, Emami (Healthy & Tasty), Health Aid, Troovy, The Healthy Factory, Healthy Master, Healthy Choice, Plan B Foods, and Neuherbs.

Violation Of Food Safety In India

Also read: FSSAI Tightens Food Safety Norms, Mandates Food-Grade Knives, Cutting Tools

HealthandMe had reported food contamination from Indore's Bhagirathpura, the same place that was the epicenter of water contamination that claimed many lives. HealthandMe also reported the news of Horlicks adulteration in Odisha.

In another news, bacteria were found in Amul milk packages, along with Mother Dairy and Country Delight. Eggoz, too, landed in a controversy, when a YouTube video went viral claiming that the sample tested positive for Nitrofuran.

MicrobioTx, a Bengaluru-based gut health startup, tested samples from urban populations across 9 Indian states and 14 cities and found that people are significantly exposed to pesticides, insecticides, antibiotics, steroidal growth regulators, and forever chemicals.

The independent study reported the following findings:

• 78% were exposed to pesticide residues, with 36% exposed to three or more pesticides, indicating cumulative exposure that may pose serious health risks.

• 54% showed presence of antibiotics, linked to antimicrobial resistance, harder-to-treat infections, and disruption of the gut microbiome that may contribute to metabolic disorders.

• 39% were exposed to steroids, compounds that may cause endocrine disruption, and increased carcinogenic risk.

• 38% tested positive for forever chemicals, persistent toxins that may cause cancer risk, reduced fertility, thyroid disease, hormone suppression, high cholesterol, liver damage, and ulcerative colitis.

• 17% of the samples had 10 or more toxins in their blood across 3 categories, indicating hidden chronic exposure.